Ipsen S.A. (EPA:IPN)
France
· Delayed Price · Currency is EUR | Market Cap | 13.55B |
| Revenue (ttm) | 3.93B |
| Net Income (ttm) | 443.50M |
| Shares Out | 82.10M |
| EPS (ttm) | 5.32 |
| PE Ratio | 31.03 |
| Forward PE | 12.90 |
| Dividend | 1.40 (0.87%) |
| Ex-Dividend Date | Jun 4, 2025 |
| Volume | 282,586 |
| Average Volume | 105,126 |
| Open | 160.80 |
| Previous Close | 160.50 |
| Day's Range | 160.70 - 165.10 |
| 52-Week Range | 87.95 - 165.10 |
| Beta | 0.27 |
| RSI | 83.77 |
| Earnings Date | Feb 12, 2026 |
About Ipsen
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injection for the treatment of pancreatic cancer; Decapeptyl for the treatment of advanced metastatic prostate cancer; Tazverik, a chemotherapy-free EZH2a i... [Read more]
Full Company ProfileFinancial Performance
In 2025, Ipsen's revenue was 3.93 billion, an increase of 9.92% compared to the previous year's 3.57 billion. Earnings were 443.50 million, an increase of 28.22%.
Financial StatementsNews
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment Ipsen_Consolidated financial statements 2025_GB
Ipsen SA (IPSEY) Full Year 2025 Earnings Call Highlights: Strong Sales Growth and Strategic ...
Ipsen SA (IPSEY) Full Year 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Innovations
Full Year 2025 Ipsen SA Earnings Call Transcript
Full Year 2025 Ipsen SA Earnings Call Transcript
Ipsen S.A. (IPSEY) Q4 2025 Earnings Call Transcript
Ipsen S.A. (IPSEY) Q4 2025 Earnings Call Transcript
Ipsen S.A. 2025 Q4 - Results - Earnings Call Presentation
Ipsen S.A. Non-GAAP EPS of €12.09, revenue of €3.68B; sets full-year 2026 guidance and mid-term outlook
Ipsen S.A. (IPSEY) Q3 2025 Earnings Call Transcript
Ipsen S.A. (OTCPK:IPSEY) Q3 2025 Earnings Call October 22, 2025 7:00 AM EDT Company Participants David Loew - MD, CEO & Director Aymeric Le Chatelier - Executive VP & CFO Christelle Huguet - Executive...
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025)
Ipsen S.A. publishes its 2025 Half-Year Report (half-year ended 30 June 2025) Attachment 2025 Half-year Financial Report_Ipsen SA
Ipsen S.A. - Initiation of the share buy-back program
Regulated information Ipsen initiates a share buy-back program to cover its free employee share-allocation plan PARIS, FRANCE, 2 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that ...
Ipsen S.A. - Annual General Meeting held on 21 May 2025
Annual General Meeting of Ipsen S.A. held on 21 May 2025 All the resolutions submitted to the shareholders' vote have been adopted PARIS, FRANCE, 21 May 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announ...
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting
Information relating to the holding of the Combined Shareholders' Meeting of 21 May 2025 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting PARIS, FRANC...
Ipsen S.A. (IPSEY) Q1 2025 Earnings Call Transcript
Ipsen S.A. (OTCPK:IPSEY) Q1 2025 Results Conference Call April 16, 2025 8:00 AM ET Company Participants David Loew - Chief Executive Officer Aymeric Le Chatelier - Chief Financial Officer Conference C...
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance
PARIS, FRANCE, 16 April 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents sales for the first quarter of 2025.
Ipsen S.A. (IPSEY) Q4 2024 Earnings Call Transcript
Ipsen S.A. (OTCPK:IPSEY) Q4 2024 Earnings Call February 13, 2025 7:00 AM ET Company Participants David Loew - Chief Executive Officer Aymeric Le Chatelier - Chief Financial Officer Christelle Huguet -...
Employee of French drugmaker Ipsen to plead guilty to US insider trading
An employee of French drugmaker Ipsen has agreed to plead guilty to illegally making more than $262,000 by trading on inside information he learned about his company's plans to acquire cancer drug dev...
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)
Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) Attachment 2024 Ipsen Half-Year Financial Report
Annual General Meeting of Ipsen S.A. held on 28 May 2024
PARIS, FRANCE, 28 May 2024 - The Annual General Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY) was held today at the Salons de l'Hôtel des Arts et Métiers, 9 bis, avenue d'Iéna, 75116 Paris (France...
Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.'s Annual General Meeting on 28 May 2024
PARIS, FRANCE, 28 May 2024 - In accordance with the provisions of Article L.22-10-62 et seq. of the French Commercial Code, the European Regulation (EU) No 596/2014 of the European Parliament and of t...
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting
Information relating to the holding of the Combined Shareholders' Meeting of 28 May 2024 of Ipsen S.A. Formalities for making available and consulting preparatory documents to the Meeting BOULOGNE-BIL...
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024.
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
Ipsen S.A. - 2023 Consolidated Financial Statements Attachment Ipsen - 2023 Consolidated Financial Statements
US FDA approves Ipsen's rare bone disorder drug
The U.S. Food and Drug Administration on Wednesday approved French drugmaker Ipsen's bone disorder drug, making it the first treatment available to patients with the rare condition that causes abnorma...
US FDA approves Ipsen's SohonosTM (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva
PARIS, FRANCE, 16 August 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicated fo...